DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
The Effects of Beta-Diethylaminoethyl-Diphenylpropylacetate (SKF-525-A) on Sickling in vitro
Technical rept. Oct 1971-Jun 1972
EDGEWOOD ARSENAL ABERDEEN PROVING GROUND MD
Pagination or Media Count:
Beta-diethylaminoethyl-diphenylpropylacetate SKF-525-A, a surface- active agent, inhibits sickling of erythrocytes from individuals with homozygous sickle cell anemia SS cells in vitro. Sickling was prevented when SS cells were incubated in .0003 M SKF-525-A, washed free of excess drug, and then deoxygenated in humidified nitrogen atmosphere. Polymerization of sickle hemoglobin and submembrane vesicles could be demonstrated in these cells by electron microscopy. At .0003 M SKF-525-A approximately 10 of the cells lysed. Incubation of pretreated cells at 37C without added oxygen for 24 hours did not produce significant additional lysis. Irreversibly sickled cells were unaffected by drug treatment. Preliminary studies suggest that the oxygen affinity of sickle hemoglobin in the intact cell is not altered by SKF-525-A. It is hypothesized that inhibition of sickling is the result of drug-induced alterations of the cell membrane.
APPROVED FOR PUBLIC RELEASE